Abstracts tagged "Intervention"

Abstract Number: 2737 • 2013 ACR/ARHP Annual Meeting
In Vivo MiR-146a Administration Ameliorates Murine Lupus Nephritis
Dong Liang¹, Shiyu Zhou², Zheng Liu³, Zhengyuan Shan¹, Philip Brohawn³, Yihong Yao³, Indu Raman⁴, Quan-Zhen Li⁴, John B. Harley^5,6 and Nan Shen^1,2,7, ¹Division of Rheumatology & the Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Shanghai Institutes for Biological Sciences Chinese Academy of Sciences & Shanghai Jiao Tong University School of Medicine, Shanghai, China, ³Translational Sciences, MedImmune, LLC, Gaithersburg, MD, ⁴Department of Immunology and Microarray Core Facility, University of Texas Southwestern Medical Center, Dallas, TX, ⁵Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁶US Department of Veterans Affairs Medical Center, Cincinnati, OH, ⁷Shanghai Institute of Rheumatology, Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
Background/Purpose: New Zealand black and white F1 (NZBW/F1) is a classic mouse model of systemic lupus erythematosus (SLE). Type I interferon (IFN) infusion accelerates lupus…
Abstract Number: 2722 • 2013 ACR/ARHP Annual Meeting
In Vivo Administration Of MiR-146a Protects C57BL/6 Mice From Pristane-Induced Pulmonary Hemorrhage Via Suppressing Type I Interferon Response
Dong Liang¹, Shiyu Zhou², Zheng Liu³, Zhengyuan Shan¹, Philip Brohawn³, Yihong Yao³, John B. Harley^4,5 and Nan Shen^1,2,6, ¹Division of Rheumatology & the Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Shanghai Institutes for Biological Sciences Chinese Academy of Sciences & Shanghai Jiao Tong University School of Medicine, Shanghai, China, ³Translational Sciences, MedImmune, LLC, Gaithersburg, MD, ⁴Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁵US Department of Veterans Affairs Medical Center, Cincinnati, OH, ⁶Shanghai Institute of Rheumatology, Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
Background/Purpose: miR-146a as an endogenous regulator plays a critical role in resolving acute inflammation. The risk-associated genetic variant in miR-146a promoter was linked to reduced…
Abstract Number: 2091 • 2013 ACR/ARHP Annual Meeting
Adaptation and Preliminary Testing of An Arthritis Walking Program to Reduce Joint Pain for Elderly Breast Cancer Survivors On Aromatase Inhibitor Therapy
Kirsten A. Nyrop¹, Betsy Hackney¹, Rebecca J. Cleveland¹, Mary Altpeter², Hyman Muss³ and Leigh F. Callahan⁴, ¹Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, ²UNC Center for Health Promotion and Disease, University of North Carolina at Chapel Hill, Chapel Hill, NC, ³Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁴Thurston Arthritis Res Ctr, University of North Carolina, Chapel Hill, NC
Background/Purpose: Joint pain/stiffness/achiness (arthralgia) is a common side-effect among postmenopausal women with breast cancer (BC) who are hormone receptor positive (HR+) for whom standard adjuvant…
Abstract Number: 2098 • 2013 ACR/ARHP Annual Meeting
What Elements Of Physical Therapy Interventions Contribute To Improved Outcomes Following Total Knee Arthroplasty
Joshua K Johnson¹, Traci E DeWan¹, Kelly L Donahue¹, Wenjun Li², Patricia D. Franklin² and Carol A. Oatis¹, ¹Physical Therapy, Arcadia University, Glenside, PA, ²Orthopedics and Physical Rehabilitation, University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Functional outcomes are variable among patients following total knee arthroplasty (TKA). Evidence is lacking to support best practices in rehabilitation to optimize functional outcomes.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].